SCHEMBL3448986

SCHEMBL3448986

CCOC(=O)c1cncc(-c2cnc(Nc3ccc(F)c(Cl)c3)nc2-n2nc(C)cc2C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN3 Q9UGI6 1/20 0.42
FGFR1 P11362 2/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
P2RY12 Q9H244 1/20 0.41
PAK1 Q13153 1/20 0.40
RAB9A P51151 2/20 0.40
XBP1 P17861 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449043 0.92 FGFR1 (0.39) FGFR1EGFRERBB2P2RY12PAK1
SCHEMBL3449052 0.92 RXFP1 (0.41) KCNN3FGFR1TSHRKMT2AMEN1
SCHEMBL3448702 0.92 SYK (0.44) FGFR1EGFRERBB2P2RY12PAK1
SCHEMBL3434606 0.89 KCNN3 (0.46) KCNN3EGFRL3MBTL1
SCHEMBL3447262 0.88 RXFP1 (0.40) FGFR1EGFRERBB2P2RY12PAK1
SCHEMBL3449379 0.88 FGFR1 (0.38) FGFR1EGFRERBB2P2RY12PAK1
SCHEMBL3448523 0.87 P2RY12 (0.43) FGFR1KMT2AMEN1EGFRERBB2
SCHEMBL3435889 0.87 FGFR1 (0.44) FGFR1KMT2AMEN1SMN1; SMN2EGFR
SCHEMBL3448621 0.86 P2RY12 (0.48) FGFR1EGFRERBB2P2RY12PAK1
SCHEMBL3449488 0.86 P2RY12 (0.48) FGFR1EGFRERBB2P2RY12PAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD KCNN3 3038/4885FGFR1 3917/4885TSHR 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.